Full-Time

Associate Director

Central Monitor, Hybrid

Updated on 8/24/2026

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$141.5k - $268.5k/yr

Waukegan, IL, USA + 2 more

More locations: Livingston, NJ, USA | Irvine, CA, USA

Hybrid

Hybrid role; on-site Tue-Thu; must be local to Lake County IL, Irvine CA, or Florham Park NJ.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Word/Pages/Docs
Risk Management
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelors degree in related field, may include life sciences, risk-based discipline.
  • Minimum of 10 years of clinically related experience or data trend analysis experience, at least 5 years people management experience (remote experience preferred).
  • Experience working in an RBQM-model or similar experience with risk-based monitoring required.
  • Experience/exposure to drug development, operations, risk management, successful decision-making, strategic execution.
  • Proven leadership skills in a cross-functional global team environment.
  • Experience in managing remote/virtual teams and an ability to influence and align stakeholders, while modeling and driving AbbVie’s leadership attributes.
  • Ability to remove obstacles and provide support that enables direct reports to achieve results.
  • Able to successfully coach and mentor both with direct reports and in a matrix environment.
  • Respectfully provides transparent, accurate and timely feedback to help direct reports improve performance.
  • Strong analytical and critical thinking skills and the ability to evaluate complex issues from multiple perspectives and drive SMART SURE decision making and timely outcomes.
  • Ability to anticipate and address critical issues; and develop contingency plans in a proactive manner.
  • Acts with integrity in accordance with ABBVIE code of business conduct.
  • Evangelist for RBQM within the organization, promoting value of early detection in de-risking studies.
  • Strong English language skills—spoken, written, and conversational.
  • Lead dynamic meetings and create engaging presentations.
  • Excellent interpersonal skills with the ability to communicate persuasively and with clarity, flexibility, and adaptability to changing requirements, resourcefulness, and creativity. Demonstrated proactive and positive team player.
  • Able to maintain calm, cool, collected, and competent composure in high pressure situations in order to ensure successful hand-off to stakeholders responsible for taking action.
  • Open and receptive to the gift of feedback in the pursuit of continuous improvement.
  • Exhibits strong planning and organizational skills and high level of flexibility in a dynamic environment with competing projects and deadlines.
  • Comfortable with use/operation of data analytics and visualization tools for oversight.
  • Competent with Microsoft Office applications (Outlook, Word, Excel, PowerPoint, and Teams).
  • On-site three days a week location requirement: Lake County, IL; Irvine, CA or Florham Park, NJ.
Responsibilities
  • Responsible for maximizing value and efficiently utilizing AbbVie’s most valuable resource (staff) in the front-line Central Monitoring space. Leads, manages, and supervises a combined team of Central Monitoring Managers with delivery responsibilities for a portfolio of studies.
  • Creates an internal leadership talent pipeline and mentors/coaches team members on their leadership journey
  • Fosters a growth mindset within the team based on inclusive collaboration, innovation, learning and continuous improvement that delivers successful outcomes for the study, the team, the individual and the business.
  • Develops the central monitoring staffing strategy and tactics in support of assigned clinical research programs, to ensure execution is with quality and efficiency, on-time, and in line with company objectives.
  • Executes and manages the central monitoring staffing strategy including fluidly adjusting plans in support of project priorities and/or timelines plan.
  • Recruits, hires, and trains the front-line Central Monitoring Leadership team, including therapeutic area training, compliance training and study management-specific knowledge as required to perform assigned tasks.
  • Manages the performance cycle including expectation setting, objective setting (both tactical and stretch opportunities to ensure continuous growth), the provision of constructive and timely feedback (informal & formal, direct feedback as well as feedback from CDO business partners) reviews and management of any performance issues to resolution.
  • Interacts with and influences all levels of management and cross-functional team members in Clinical Development Operations to achieve high standards of output from front-line Central Monitoring Leadership staff.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.